GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » Cyclically Adjusted PB Ratio

Ionis Pharmaceuticals (FRA:ISI) Cyclically Adjusted PB Ratio : 7.15 (As of May. 24, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Ionis Pharmaceuticals's current share price is €34.54. Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €4.83. Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 7.15.

The historical rank and industry rank for Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:ISI' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.09   Med: 18.99   Max: 46.58
Current: 7.45

During the past years, Ionis Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 46.58. The lowest was 6.09. And the median was 18.99.

FRA:ISI's Cyclically Adjusted PB Ratio is ranked worse than
85.58% of 652 companies
in the Biotechnology industry
Industry Median: 1.74 vs FRA:ISI: 7.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €1.870. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.83 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.87 14.17 6.78 7.54 9.99

Ionis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 7.99 8.86 9.99 8.50

Competitive Comparison of Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=34.54/4.83
=7.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ionis Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.87/131.7762*131.7762
=1.870

Current CPI (Mar. 2024) = 131.7762.

Ionis Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.295 100.560 3.007
201409 2.268 100.428 2.976
201412 1.765 99.070 2.348
201503 2.131 99.621 2.819
201506 2.232 100.684 2.921
201509 1.822 100.392 2.392
201512 1.532 99.792 2.023
201603 1.177 100.470 1.544
201606 0.819 101.688 1.061
201609 1.027 101.861 1.329
201612 0.776 101.863 1.004
201703 1.523 102.862 1.951
201706 1.545 103.349 1.970
201709 2.073 104.136 2.623
201712 1.900 104.011 2.407
201803 1.948 105.290 2.438
201806 4.345 106.317 5.385
201809 4.428 106.507 5.479
201812 6.679 105.998 8.303
201903 7.655 107.251 9.406
201906 8.002 108.070 9.757
201909 8.628 108.329 10.495
201912 9.434 108.420 11.466
202003 8.838 108.902 10.694
202006 8.767 108.767 10.622
202009 8.400 109.815 10.080
202012 4.353 109.897 5.220
202103 4.057 111.754 4.784
202106 3.429 114.631 3.942
202109 3.194 115.734 3.637
202112 4.837 117.630 5.419
202203 4.545 121.301 4.937
202206 4.167 125.017 4.392
202209 4.227 125.227 4.448
202212 3.807 125.222 4.006
202303 3.178 127.348 3.289
202306 2.761 128.729 2.826
202309 2.061 129.860 2.091
202312 2.457 129.419 2.502
202403 1.870 131.776 1.870

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ionis Pharmaceuticals  (FRA:ISI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (FRA:ISI) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (FRA:ISI) Headlines

No Headlines